AbbVie Buy Rating Affirmed Despite Emraclidine Setback, Driven by Skyrizi and Rinvoq Growth
Terence Flynn, an analyst from Morgan Stanley, reiterated the Buy rating on AbbVie (ABBV – Research Report). The associated price target ...
Buy, Sell, Or Hold BMY Stock?
This was partly offset by a 1% rise in the company’s revenue from $46 billion to $47 billion over the same period; and a 4.1% ...
The Globe and Mail2d
Is This Dividend King a Buy After a Strong Q3 Report?
While Humira is losing steam after its patent expiration, AbbVie has prepared for a future beyond this blockbuster. It has ...
Positive Long-Term Growth Outlook for AbbVie Despite Emraclidine Setback: Analyst Maintains Buy Rating
Analyst Carter Gould of Barclays maintained a Buy rating on AbbVie (ABBV – Research Report), retaining the price target of $212.00.
What's Going On With Bristol-Myers Squibb Shares Monday?
Bristol-Myers Squibb Co (NYSE:BMY) shares are trading higher Monday. The stock appears to be reacting positively after AbbVie ...
Medindia3d
AbbVie Provides Update on Phase 2 Results for Emraclidine in Schizophrenia
In the EMPOWER trials, emraclidine was well-tolerated with a safety profile comparable to that observed in the Phase 1b trial. The most commonly reported adverse events in EMPOWER-1 and EMPOWER-2, ...
3 Spectacular High-Yield Dividend Stocks to Buy in November
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...